Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
EVMNthis companyEvommune, Inc.	$7.44	-1.53×	0.51×	8.08×	-0.79×	-2667.3%	100.0%	-623.6%	-529.8%	-33.5%	-39.1%	-73.0%	0.01×	0.53×	0×	8.57×	0.0%	4	4.4	2	C+
ARTVArtiva Biotherapeutics, Inc.	$4.22	-1.25×	0.95×	0×	-1.1×	-84.3%	0.0%	0.0%	0.0%	-76.3%	-74.9%	-75.7%	0.1×	0.19×	0×	8.61×	0.0%	1	4.66	2	C+
CDXSCodexis, Inc.	$1.13	-3.26×	2.81×	2.02×	-4.86×	-459.7%	86.7%	-54.5%	-62.5%	-87.0%	-30.6%	-16.8%	1.45×	-0.66×	-7.96×	3.82×	0.0%	3	-6.21	1	D+
CLYMClimb Bio, Inc.	$11.19	-4.55×	1.69×	0×	-3.95×	-95.0%	0.0%	0.0%	0.0%	-37.3%	-42.2%	-20.1%	0×	0.59×	0×	15.16×	0.0%	2	48.03	2	C
EYPTEyePoint Pharmaceuticals, Inc.	$0.35	-5.76×	4.37×	42.66×	-5.49×	-1218.8%	93.4%	-776.0%	-739.4%	-75.8%	-74.0%	-18.2%	0.07×	0.34×	0×	8.88×	0.0%	2	-11.09	1	C-
FTREFortrea Holdings Inc.	$22.74	-1.6×	2.79×	0.58×	-3.09×	-197.3%	15.6%	-1.1%	-36.2%	-175.0%	-1.7%	5.6%	1.98×	-1.16×	-0.33×	0.98×	0.0%	5	0.78	1	C-
Peer median	—	-3.26×	2.79×	0.58×	-3.95×	-197.3%	15.6%	-1.1%	-36.2%	-76.3%	-42.2%	-18.2%	0.1×	0.19×	0×	8.61×	0.0%	2	0.78	1	—